pteridines has been researched along with gsk 461364 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbott, NJ; Bertone, P; Danovi, D; Elbatsh, AM; Ender, C; Engström, PG; Ferretti, P; Folarin, A; Gagrica, S; Georgian, A; Gogolok, S; Harvey, KJ; Paddison, PJ; Pollard, SM; Preston, JE; Smith, A; Stricker, SH; U, KP; Yu, D | 1 |
| Bogado, RF; Brassesco, MS; de Oliveira, HF; Pezuk, JA; Tone, LG | 1 |
| Shin, SB; Woo, SU; Yim, H | 1 |
| Byers, LA; Diao, L; Ferrarotto, R; Gibbons, DL; Girard, L; Giri, U; Glisson, BS; Goonatilake, R; Heymach, JV; Johnson, FM; Li, L; Minna, J; Peng, DH; Peng, S; Tong, P; Wang, J; Wang, L; Wang, Y; Yoo, SY | 1 |
| Althoff, K; Dreesmann, S; Eggert, A; Schramm, A; Schulte, JH; Schwermer, M; Steenpass, L; Temming, P | 1 |
| Lee, YJ; Shin, SB; Woo, SU; Yim, H | 1 |
| Brassesco, MS; Pezuk, JA; Roberto, GM; Salomão, KB; Scrideli, CA; Tone, LG | 1 |
| Chou, TC; Huang, YT; Lin, JD; Lin, SF; Wong, RJ; Yeh, CN | 1 |
8 other study(ies) available for pteridines and gsk 461364
| Article | Year |
|---|---|
A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.
Topics: Animals; Benzimidazoles; Blood-Brain Barrier; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Indans; Mice; Mice, Knockout; Neoplastic Stem Cells; Neural Stem Cells; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Small Molecule Libraries; Swine; Thiophenes; Tumor Suppressor Protein p53 | 2013 |
BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Bone Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Osteosarcoma; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radiation Tolerance; Radiation-Sensitizing Agents; Thiophenes | 2015 |
Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzoates; Benzoquinones; Binding Sites; Catalytic Domain; Cell Cycle Proteins; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Design; Female; G2 Phase Cell Cycle Checkpoints; HeLa Cells; Humans; Inhibitory Concentration 50; Mitosis; Molecular Targeted Therapy; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins; Pteridines; Quinones; S Phase Cell Cycle Checkpoints; Signal Transduction; Thiophenes; Time Factors; Uterine Cervical Neoplasms | 2015 |
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Topics: Animals; Apoptosis; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Chromosomal Instability; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Mice; Mutation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pteridines; Thiophenes; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Blotting, Western; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin-Dependent Kinases; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Phosphorylation; Polo-Like Kinase 1; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Real-Time Polymerase Chain Reaction; Retinal Neoplasms; Retinoblastoma; Thiophenes; Tumor Cells, Cultured | 2017 |
Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biological Assay; Biomarkers, Tumor; Cell Cycle Proteins; Drug Evaluation, Preclinical; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; Genistein; Glutathione Transferase; Humans; Insecta; Peptides; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radioisotopes; Thiophenes; Tumor Protein, Translationally-Controlled 1 | 2017 |
PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Radiation-Sensitizing Agents; Thiophenes | 2018 |
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Sorafenib; Thiophenes; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |